MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Analysis of the olfactory impairments in PINK1 deficient mice

    A. Hummel, A. Zimprich, L. Garret, B. Sperling, F. Giesert, J. Nagler, H. Fuchs, V. Gailus-Durner, M. Hrabé de Angelis, S.M. Koch, D. Vogt Weisenhorn, W. Wurst (Neuherberg, Germany)

  • Anhedonia and its correlation with clinical aspects in Parkinson’s disease

    H. Nagayama (Tokyo, Japan)

  • Anosmia predicts development of more severe motor symptoms including freezing of gait and impaired balance at 2 year follow-up in PD

    N.I. Bohnen, J. Haugen, V. Kotagal, K.A. Frey, R.L. Albin, M.L.T.M. Muller (Ann Arbor, MI, USA)

  • Anti-GAD antibody cerebellar ataxia mimicking multiple system atrophy

    J.B. Parmera, L.S.V. Schneider, R.G. Cury, M.M. Simabukuro, L.H.M. Castro, E.R. Barbosa (São Paulo, Brazil)

  • Anti-LGI1 encephalitis presenting as a progressive supranuclear palsy-like syndrome

    G.A. Da Prat, E.M. Gatto, G.G. Persi, V. Parisi, D. Lisei, L. Rattagan, M. Bres Bullrich, S. Camerlingo, C. Rugilo, M. Titulaer, G. Rojas (Caba, Argentina)

  • AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

    E.Y. Pioli, W.K.D. Ko, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

  • AntiParkinsonian effects of the “radiprodil and tozadenant” combination in MPTP-treated marmosets

    A. Michel, J.M. Nicolas, S. Rose, M. Jackson, P. Colman, W. Briône, D. Sciberras, P. Muglia, D. Scheller, M. Citron, P. Downey (Braine L'Alleud, Belgium)

  • AntiParkinsonian medication adjustments following deep brain stimulation of subthalamic nucleus in patients with advanced Parkinson’s disease

    A. Gamaleya, E. Bril, A. Tomskiy, A. Poddubskaya, N. Gubareva, N. Fedorova, V. Shabalov (Moscow, Russia)

  • AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

    L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

  • Anxiety and cognition are associated with dopaminergic dysfunction in de novo Parkinson’s disease

    M. Picillo, G. Santangelo, R. Erro, A. Cozzolino, M. Amboni, C. Vitale, P. Barone, M.T. Pellecchia (Baronissi, Italy)

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 207
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley